society

Bayer deepens integration into China’s economic, societal development


Staff members work in a physical and chemical lab at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a secondary packaging workshop at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a physical and chemical lab at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a secondary packaging workshop at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member observes the microscopic features of a product under research at a research and development center at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member is pictured at the research and development center of Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Staff members are seen at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Staff members weigh raw materials at a solids workshop at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a granulation workshop at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a physical and chemical lab at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a primary packaging workshop at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member tests a product’s solubility at the research and development center of Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Two staff members walk past a company emblem at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Staff members work in a physical and chemical lab at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a microbiological lab at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member is pictured at the research and development center of Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Staff members test reagent research equipment at a research and development center at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member works in a primary packaging workshop at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Staff members work in a physical and chemical lab at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

A staff member observes the microscopic features of a product under research at a research and development center at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China’s Jiangsu Province, Dec. 2, 2020. Bayer, an innovative company with core competencies in health care and agriculture, has not only stepped up its investment in the Chinese market, but also deepened its integration into China’s economic and societal development. Like other foreign investors, Bayer has been given equal treatment by the Chinese government, which encourages innovation and cooperation. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer’s production and operation activities in China and has also increased Bayer’s confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. China has vowed to pursue high-level opening up and leverage the advantages of its huge market to promote international cooperation for win-win results in the span of the upcoming 14th Five-Year Plan. The aim is to turn the country’s market into a market for the world, a market shared by all, and a market accessible to all. “Bayer will capitalize on the opportunities brought by China’s opening-up, and will continue to work closely with the Chinese government and local partners on innovation and manufacturing of high quality products in both healthcare and agricultural sectors. We look forward to continued success for China as a country, and for Bayer as a company,” said Wei Jiang, President of Bayer Group Greater China. (Xinhua/Zhang Yuwei)

Related posts

China Focus: Rain-ravaged Henan activates highest-level emergency response

xxx

Beijing starts COVID-19 vaccination among key groups

xxx

China’s Jilin clears areas with medium COVID-19 risks

xxx